Clinical Trials on Advanced Hematologic Malignancies

Total 21520 results

A.O. Ospedale Papa Giovanni XXIII
Regional Hospital of Bolzano; Azienda Ospedaliera San Gerardo di Monza

Completed

Cytokine Induced Killer (CIK) Cells In Leukemia Patients (CIK2)

Hematologic Malignancies

Italy
University Hospital, Limoges

Recruiting

Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies (AROM-HEMATO)

Hematological Malignancies

France
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Infectious Diseases | Hematological Malignancies

China
University Hospital of Cologne

Recruiting

Cologne Cohort of Neutropenic Patients (CoCoNut) (CoCoNut)

Cancer | Neutropenia | Chemotherapy | Hematological Malignancies | Immunosuppression

Germany
Leuko Labs, Inc.
M.D. Anderson Cancer Center; Center for Advancing Point of Care Technologies...

Recruiting

Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population (PC004)

Hematologic Malignancy

United States
CRISPR Therapeutics AG

Enrolling by invitation

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Hematologic Malignancy | Solid Malignancy

United States, Australia
Chinese PLA General Hospital

Completed

GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor

Solid Tumor | Hematologic Malignancy

China
Piramal Enterprises Limited

Completed

A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies (Serenity)

Solid Tumor | Hematologic Malignancy

India
A.O. Ospedale Papa Giovanni XXIII

Recruiting

Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant (Haplo-CIK)

Relapsed Hematologic Malignancy

Italy
Kiromic, Inc.

Withdrawn

Therapy for Progressive and/or Refractory Hematologic Malignancies

Cancer | Hematologic Malignancies
Mayo Clinic

Recruiting

Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study

Solid Tumors | Hematologic Malignancies

United States
Novartis Pharmaceuticals

Terminated

BGJ398 for Patients With Tumors With FGFR Genetic Alterations (CBGJ398XUS04)

Solid Tumor | Hematologic Malignancies

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

Solid Tumors | Hematologic Malignancies

Netherlands
Mount Sinai Hospital, Canada

Active, not recruiting

Critical Care Outcomes of Hematologic Oncology Patients (COHO)

Stem Cell Transplant | Hematologic Malignancy

Canada
Atridia Pty Ltd.

Completed

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Solid Tumors and Hematologic Malignancy

Australia
Incyte Corporation

Completed

Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

Solid Tumors and Hematologic Malignancy

United States
Rabin Medical Center

Unknown

Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation

Hematological Malignancy | Bone Marrow Failure Syndrome

Israel
Stanford University

Completed

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

Leukemia | Blood Cancer

United States
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

rrCLL | rrMM | rrDLBCL
Centre Francois Baclesse

Completed

Telephone OncoGériatric Followed in the Management of Elderly Patients Treated for Cancer or Haematological Malignancy (TelOG)

Cancer | Hematologic Malignancy

France
Centre Hospitalier Universitaire de Besancon
Etablissement Français du Sang; Bellicum Pharmaceuticals

Unknown

T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. (Side_by_Cide)

Hematological Malignancies | Graft Versus Host Disease

France
Assistance Publique - Hôpitaux de Paris

Completed

Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies (LYMPHCORD)

Patients With Advanced Lymphoid Malignancies in the Absence of an HLA Identical or Mismatch Donor

France
Firas El Chaer, MD

Recruiting

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

Hematologic Malignancy | Platelet Refractoriness

United States
Northside Hospital, Inc.

Recruiting

GM-CSF With Post-Transplant Cyclophosphamide

Transplant-Related Hematologic Malignancy

United States
Dialectic Therapeutics, Inc

Completed

A Study of DT2216 in Relapsed/Refractory Malignancies

Solid Tumor | Hematologic Malignancy

United States
Institut de cancérologie Strasbourg Europe

Completed

Follow-up of Actual Patient Care Site Two Months After Hospitalisation Compared With Their Expressed Choice Regarding Subsequent Care Site (RESPECT) (RESPECT)

Hematologic Malignancy | Tumor, Solid

France
M.D. Anderson Cancer Center
BTG International Inc.

Terminated

Voraxaze for Delayed Methotrexate Clearance

Solid Tumor | Hematologic Malignancy

United States
Mansoura University

Completed

Prognosis of Hematological Cancer Patient Underwent Mechanical Ventillation

Acute Respiratory Failure | Mechanical Ventilation | Hematological Malignancy

Egypt
AstraZeneca

Terminated

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Haematological Malignancies

France, Italy, United States, Korea, Republic of, Germany, Australia
St. Jude Children's Research Hospital

Recruiting

Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products

Refractory Hematologic Malignancy | Relapsed Hematologic Malignancy

United States
Massachusetts General Hospital
Medically Home

Active, not recruiting

Hospital at Home at EOL in Heme Malignancies

Hematologic Malignancy

United States
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Terminated

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Hematologic Malignancy

China
Medical College of Wisconsin
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

Hematologic Malignancy

United States
Massachusetts General Hospital

Active, not recruiting

CAR T-CELL Therapy Educational Video Trial

Hematologic Malignancy | CAR-T Cell Therapy

United States
Scripps Translational Science Institute

Completed

Scripps Tumorgraft Study

Solid Tumor Malignancy or Hematologic Malignancy

United States
Assistance Publique - Hôpitaux de Paris
National Cancer Institute, France; Canceropôle Ile de France; Oncogeriatric Coordination... and other collaborators

Recruiting

Elderly CAncer Patient (ELCAPA)

Hematologic Malignancies | Solid Cancer

France
Pfizer

Terminated

LGX818 for Patients With BRAFV600 Mutated Tumors (SIGNATURE)

Solid Tumor | Hematologic Malignancies

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.

Completed

Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation

Hematologic Malignancies | Malignant Solid Tumor

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

Hematopoietic/Lymphoid Cancer

United States
Vividion Therapeutics, Inc.

Recruiting

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

Advanced Solid Tumors | Advanced Hematologic Tumors

United States, Spain, Australia
Beijing 302 Hospital

Not yet recruiting

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

Hematological Malignancies | Graft-versus-host Disease
NYU Langone Health

Terminated

Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft

Hematopoietic Malignancies

United States
EMD Serono

Terminated

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

Haematological Malignancies

Italy, United States, Switzerland, Belgium, Germany
Henan Cancer Hospital
Nanjing Bioheng Biotech Co., Ltd.

Recruiting

RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies

Hematologic Malignancies

China
National Cancer Institute (NCI)

Enrolling by invitation

Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

Solid Tumors | Hematologic Malignancies | Pediatric Cancers

United States
Memorial Sloan Kettering Cancer Center

Completed

Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies

Lymphoma | Leukemia | Myelodysplastic Syndrome

United States
Cellect Biotechnology

Unknown

Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation

Hematological Malignancies

Israel
Fondazione del Piemonte per l'Oncologia

Unknown

Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant

Hematological Malignancies

Italy
Nationwide Children's Hospital

Recruiting

αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT) (TB19DHCT)

Hematologic Malignancy | Hematopoietic Stem Cell Transplantation

United States
Peking University People's Hospital

Recruiting

Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT

Hematologic Malignancy | Stem Cell Transplant Complications

China

Clinical Trials on Advanced Hematologic Malignancies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations